

Title:RSV season has ended in Oregon and clinicians may discontinue offering nirsevimab

On April 26, Oregon met criteria for respiratory syncytial virus (RSV) season offset. While RSV continues to circulate at very low levels, clinicians may discontinue offering nirsevimab.

Oregon Health Authority (OHA) advises the use of local epidemiology to guide nirsevimab timing. Nirsevimab provides approximately five months of protection against RSV infection and timing of administration is critical to providing protection throughout the RSV season. OHA will continue to send HANs alerting providers to the onset and offset of each RSV season.

Oregon's RSV Surveillance Report is available here:

<https://www.oregon.gov/oha/PH/DISEASES/CONDITIONS/COMMUNICABLE/DISEASE/SURVEILLANCE/DOCUMENTS/RSV/RSV>

Additional information regarding nirsevimab may be found here: <https://www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html>

CDC's [Respiratory Virus Guidance](#) outlines strategies for preventing transmission of viral respiratory diseases, including RSV.

For questions, please contact Melissa Sutton at Melissa.Sutton@oha.oregon.gov.